User login
Key clinical point: Nivolumab+brentuximab vedotin (BV) showed long-term efficacy and safety in patients with treatment-resistant relapsed or refractory (R/R) primary mediastinal large B-cell lymphoma (PMBL).
Major finding: After a median follow-up of 39.6 months, the objective response rate was 73.3% (95% CI 54.1%-87.7%), with 40.0% and 33.3% of patients achieving complete and partial responses, respectively. The median duration of response or overall survival was not reached, and the median progression-free survival was 26.0 (95% CI 2.6-not reached) months. No new safety signals were reported.
Study details: This 3-year follow-up study of phase 1/2 CheckMate 436 trial included 30 patients age ≥15 years with R/R PMBL previously treated with high-dose chemotherapy+autologous hematopoietic cell transplantation or ≥2 prior multiagent chemotherapies who received 240 mg nivolumab and 1.8 mg/kg BV once every 3 weeks.
Disclosures: This study was supported by Bristol Myers Squibb (BMS) and Seagen. Some authors declared serving as advisory board members and receiving consulting fees, honoraria, or research grants from BMS, Seagen, and others. Three authors declared being employees of or holding stocks in BMS or Seagen.
Source: Zinzani PL et al. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: A 3-year follow-up. Blood Adv. 2023 (Jun 23). Doi: 10.1182/bloodadvances.2023010254
Key clinical point: Nivolumab+brentuximab vedotin (BV) showed long-term efficacy and safety in patients with treatment-resistant relapsed or refractory (R/R) primary mediastinal large B-cell lymphoma (PMBL).
Major finding: After a median follow-up of 39.6 months, the objective response rate was 73.3% (95% CI 54.1%-87.7%), with 40.0% and 33.3% of patients achieving complete and partial responses, respectively. The median duration of response or overall survival was not reached, and the median progression-free survival was 26.0 (95% CI 2.6-not reached) months. No new safety signals were reported.
Study details: This 3-year follow-up study of phase 1/2 CheckMate 436 trial included 30 patients age ≥15 years with R/R PMBL previously treated with high-dose chemotherapy+autologous hematopoietic cell transplantation or ≥2 prior multiagent chemotherapies who received 240 mg nivolumab and 1.8 mg/kg BV once every 3 weeks.
Disclosures: This study was supported by Bristol Myers Squibb (BMS) and Seagen. Some authors declared serving as advisory board members and receiving consulting fees, honoraria, or research grants from BMS, Seagen, and others. Three authors declared being employees of or holding stocks in BMS or Seagen.
Source: Zinzani PL et al. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: A 3-year follow-up. Blood Adv. 2023 (Jun 23). Doi: 10.1182/bloodadvances.2023010254
Key clinical point: Nivolumab+brentuximab vedotin (BV) showed long-term efficacy and safety in patients with treatment-resistant relapsed or refractory (R/R) primary mediastinal large B-cell lymphoma (PMBL).
Major finding: After a median follow-up of 39.6 months, the objective response rate was 73.3% (95% CI 54.1%-87.7%), with 40.0% and 33.3% of patients achieving complete and partial responses, respectively. The median duration of response or overall survival was not reached, and the median progression-free survival was 26.0 (95% CI 2.6-not reached) months. No new safety signals were reported.
Study details: This 3-year follow-up study of phase 1/2 CheckMate 436 trial included 30 patients age ≥15 years with R/R PMBL previously treated with high-dose chemotherapy+autologous hematopoietic cell transplantation or ≥2 prior multiagent chemotherapies who received 240 mg nivolumab and 1.8 mg/kg BV once every 3 weeks.
Disclosures: This study was supported by Bristol Myers Squibb (BMS) and Seagen. Some authors declared serving as advisory board members and receiving consulting fees, honoraria, or research grants from BMS, Seagen, and others. Three authors declared being employees of or holding stocks in BMS or Seagen.
Source: Zinzani PL et al. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: A 3-year follow-up. Blood Adv. 2023 (Jun 23). Doi: 10.1182/bloodadvances.2023010254